Jump to content

Xofigo (radium-223) strength and length of dose trial starting in NSW, Vic, SA


Recommended Posts

Xofigo (radium-223) is a form of short-lived radiation. It is put into your blood, where it sticks to prostate cancer in bone, damaging the cancer.


Xofigo has been shown to extend life, and reduce the number of bone problems in men with castrate resistant prostate cancer.


Bayer, the company marketing Xofigo has launched a clinical trial to test whether higher or longer doses would do even better. Men accepted would be put into one of three groups: standard dose, stronger dose, or longer standard dose.


ClinicalTrials.gov has listed the trial as recruiting now, but none of the trial sites are listed as recruiting yet. Presumably they will begin any day.


The Australian sites for this trial are South Australia: Adelaide, Victoria: Melbourne, Box Hill, New South Wales: Darlinghurst, Westmead


The trial is called:

Standard Dose Versus High Dose and Versus Extended Standard Dose Radium-223 Dichloride in Castration-resistant Prostate Cancer Metastatic to the Bone


Find it here:



or search for NCT02023697


Thanks to Paul for finding details of this trial.

Link to comment
Share on other sites


This topic is now archived and is closed to further replies.

  • Create New...